Clinical Trials
102 trialsA Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
FiREBOLT
Eli Lilly and Company
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Shenzhen Xinhe Biomedical
TCR1188-ABC Cells in KRAS-mutated Cancers
University of Pennsylvania
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
A Study of MGC028 in Participants With Advanced Solid Tumors
MacroGenics
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Arbele Limited
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
M.D. Anderson Cancer Center
MAST
Imugene Limited
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Servier
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Mayo Clinic
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
AMPLIFY-201
Elicio Therapeutics
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Leap Therapeutics, Inc.
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
PIPAC-NAL-IRI
University Hospital, Ghent
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Kinnate Biopharma
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
Toray Industries, Inc
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Boehringer Ingelheim
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Zymeworks BC Inc.
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
ABM Therapeutics Shanghai Company Limited
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
SURF201
Tyra Biosciences, Inc
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
University of California, San Diego
Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin
Chang Gung Memorial Hospital
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation